Cargando…
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH
Endothelial dysfunction and reduced nitric oxide (NO) signaling are a key element of the pathophysiology of nonalcoholic steatohepatitis (NASH). Stimulators of soluble guanylate cyclase (sGC) enhance NO signaling; have been shown preclinically to reduce inflammation, fibrosis, and steatosis; and thu...
Autores principales: | Hall, Katherine C., Bernier, Sylvie G., Jacobson, Sarah, Liu, Guang, Zhang, Ping Y., Sarno, Renee, Catanzano, Victoria, Currie, Mark G., Masferrer, Jaime L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561202/ https://www.ncbi.nlm.nih.gov/pubmed/31085647 http://dx.doi.org/10.1073/pnas.1821045116 |
Ejemplares similares
-
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease
por: Zimmer, Daniel P., et al.
Publicado: (2020) -
IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model
por: Shea, Courtney, et al.
Publicado: (2015) -
SUN-662 Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Improves Lipid Handling and Insulin Sensitivity in Diet-Induced Obese Mice
por: Schwartzkopf, Chad D, et al.
Publicado: (2020) -
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats
por: Banijamali, Ali R., et al.
Publicado: (2020) -
Structural insights into sGC
por: Akker, Focco van den, et al.
Publicado: (2009)